Subclinical primary aldosteronism

被引:18
作者
Ito, Yuji [1 ]
Takeda, Ryoyu [1 ,2 ]
Takeda, Yoshiyu [2 ]
机构
[1] KKR Hokuriku Hosp, Federat Natl Publ Serv Personnel Mutual Aid Assoc, Dept Internal Med, Kanazawa Ku, Kanazawa, Ishikawa 9218035, Japan
[2] Kanazawa Univ, Grad Sch Med Sci, Dept Internal Med, Kanazawa, Ishikawa, Japan
关键词
subclinical; normotensive; normokalaemic; primary aldosteronism; NORMOTENSIVE PRIMARY ALDOSTERONISM; HYPERALDOSTERONISM TYPE-I; PLASMA-RENIN ACTIVITY; HYPERTENSIVE PATIENTS; CAPTOPRIL TEST; PREVALENCE; ADENOMA; SUPPRESSION; RESISTANCE; CARCINOMA;
D O I
10.1016/j.beem.2011.11.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Screening for primary aldosteronism was historically recommended in patients with moderate to severe and/or resistant hypertension. Patients with mild hypertension and normotensive subjects were therefore excluded from the screening. However, a considerable number of normotensive individuals without hypokalaemia may have subclinical forms of primary aldosteronism. In this review, we describe evidence supporting the idea that primary aldosteronism is not only confined to patients with moderate to severe and/or resistant hypertension, but also exists in patients with mild hypertension and even in those with normotension. We discuss possible aetiologies, screening and diagnostic techniques and treatment options of the normotensive form of primary aldosteronism. The natural history, adverse effects and best treatment of this disease still remain to be resolved. The long-term follow-up studies of normotensive primary aldosteronism patients who receive neither adrenal surgery nor treatment with mineralocorticoid receptor antagonists might help to solve these problems. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:485 / 495
页数:11
相关论文
共 54 条
  • [1] Captopril suppression versus salt loading in confirming primary aldosteronism
    Agharazii, M
    Douville, P
    Grose, JH
    Lebel, M
    [J]. HYPERTENSION, 2001, 37 (06) : 1440 - 1443
  • [2] Akiyama M, 1994, Nihon Hinyokika Gakkai Zasshi, V85, P1139
  • [3] Prevention of hypertension, cardiovascular damage and endothelial dysfunction with green tea extracts
    Antonello, Michele
    Montemurro, Domenico
    Bolognesi, Massimo
    Di Pascoli, Marco
    Piva, Anna
    Grego, Franco
    Sticchi, Daniele
    Giuliani, Luisa
    Garbisa, Spiridione
    Rossi, Gian Paolo
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2007, 20 (12) : 1321 - 1328
  • [4] HYPERALDOSTERONISM FROM ADRENAL CARCINOMA
    BROOKS, RV
    ROBERTSON, PW
    LEE, MR
    FELIXDAV.D
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1972, 1 (5794): : 220 - +
  • [5] Hyperaldosteronism among with resistant black and white subjects hypertension
    Calhoun, DA
    Nishizaka, MK
    Zaman, MA
    Thakkar, RB
    Weissmann, P
    [J]. HYPERTENSION, 2002, 40 (06) : 892 - 896
  • [6] Is there an unrecognized epidemic of primary aldosteronism? (Pro)
    Calhoun, David A.
    [J]. HYPERTENSION, 2007, 50 (03) : 447 - 452
  • [7] Diagnostic value of the post-captopril test in primary aldosteronism
    Castro, OL
    Yu, XC
    Kem, DC
    [J]. HYPERTENSION, 2002, 39 (04) : 935 - 938
  • [8] Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism
    Catena, Cristiana
    Colussi, GianLuca
    Lapenna, Roberta
    Nadalini, Elisa
    Chiuch, Alessandra
    Gianfagna, Pasquale
    Sechi, Leonardo A.
    [J]. HYPERTENSION, 2007, 50 (05) : 911 - 918
  • [9] CONN JW, 1964, JAMA-J AM MED ASSOC, V190, P213
  • [10] Primary hyperaldosteronism in essential hypertensives:: Prevalence, biochemical profile, and molecular biology
    Fardella, CE
    Mosso, L
    Gómez-Sánchez, C
    Cortés, P
    Soto, J
    Gómez, L
    Pinto, M
    Huete, A
    Oestreicher, E
    Foradori, A
    Montero, J
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (05) : 1863 - 1867